Hikma Pharmaceuticals PLC (LON:HIK) Increases Dividend to $0.48 Per Share

by · The Cerbat Gem

Hikma Pharmaceuticals PLC (LON:HIKGet Free Report) announced a dividend on Wednesday, February 26th, DividendData.Co.Uk reports. Stockholders of record on Thursday, March 20th will be paid a dividend of $0.48 per share on Thursday, May 1st. This represents a dividend yield of 1.8%. The ex-dividend date is Thursday, March 20th. This is a 50.0% increase from Hikma Pharmaceuticals’s previous dividend of $0.32. The official announcement can be seen at this link.

Hikma Pharmaceuticals Price Performance

Shares of LON HIK traded up GBX 22 ($0.29) during mid-day trading on Tuesday, hitting GBX 2,052 ($26.65). 76,300,625 shares of the company’s stock traded hands, compared to its average volume of 3,417,024. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. Hikma Pharmaceuticals has a 1 year low of GBX 1,750 ($22.73) and a 1 year high of GBX 2,360 ($30.65). The company has a market capitalization of £5.69 billion, a P/E ratio of 20.14, a PEG ratio of 2.38 and a beta of 0.41. The company’s 50-day moving average is GBX 2,177.22 and its two-hundred day moving average is GBX 2,014.40.

Wall Street Analysts Forecast Growth

HIK has been the topic of a number of recent analyst reports. Berenberg Bank reissued a “buy” rating and issued a GBX 2,560 ($33.25) price objective on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a research report on Friday, March 7th.

Check Out Our Latest Research Report on HIK

Hikma Pharmaceuticals Company Profile

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.

See Also